Trial Profile
Apatinib Dose Titration: Analyses of Exposure, Safety and Efficacy in Advanced or Metastatic Gastric Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 24 Feb 2022 Status changed from not yet recruiting to completed.
- 09 May 2016 New trial record